adrenomyeloneuropathy AMN disease
Conditions
Interventions
SAD: single dose of ABX-002 (oral solution or oral capsule) or placebo (oral
solution or capsule)
MAD: multiple doses of ABX-002 (oral solution or oral capsule) or placebo (oral
solution or capsule
Sponsors
Autobahn Therapeutics, Inc.
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 2. Male or female * 18 to * 55 years of age at the time of the Screening Visit. 7. In good health based on medical history, physical examination (including neurological examination), vital sign measurements, and laboratory safety tests obtained at Screening. 8. No clinically significant abnormality on the single ECG performed at Screening and the triplicate ECG performed prior to the first administration of study drug. Single ECG performed at Screening may be repeated once.
Exclusion criteria
Exclusion criteria: 3. Estimated creatinine clearance of * 90 mL/min based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Levey 2009). 6. History or evidence of any of the following: myocardial infarction; cardiac valvulopathy; cardiac surgery revascularization (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty); unstable angina; cerebrovascular accident, stroke, or transient ischemic attack; pacemaker; atrial fibrillation, flutter, or nonsustained or sustained VT; pulmonary arterial hypertension; sick sinus syndrome, second- or third-degree atrioventricular (AV) block; uncontrolled hypertension; congestive heart failure; personal or family history of sudden death or long QT syndrome; unexplained syncope or syncope within the last 3 years regardless of etiology; or history of hypokalemia. 8. Screening Holter monitor (24 hours) shows nonsustained VT, SVT lasting > 10 beats in a run or > 4 runs, atrial fibrillation, atrial flutter, or a pause > 4 seconds. 9. Mean pulse 100 bpm, mean systolic blood pressure >140 mm Hg, or mean diastolic blood pressure > 90 mm Hg at Screening measured in duplicate using a calibrated digital device. If the mean blood pressure exceeds the limits above, an additional set of blood pressure measurements will be obtained, and the subject may be included if pulse and BP parameters are within the permitted boundaries. 11. Troponin T out of the normal laboratory range at time of the Screening Visit. 18. Consumption of excessive amounts of caffeine, defined as > 4 servings of coffee, tea, cola, or other caffeinated beverages per day (1 serving is approximately 120 mg of caffeine). Refusal to abstain from caffeine-containing foods or caffeinated beverages (eg, coffee, tea, cola, energy drinks) 24 hours prior to Day -1 through discharge from the CRU after the final administration of study drug. 19. Refusal to abstain from grapefruit-containing foods or beverages or Seville orange-containing foods or beverages 14 days prior to Day -1 through the Follow-Up Visit 20. Refusal to abstain from consumption of cruciferous vegetables (eg, kale, broccoli, watercress, collard greens, kohlrabi, brussels sprouts, mustard greens) or charbroiled meats (meat grilled over any heat source with black marks) * 7 days prior to Day -1 through the Follow-Up Visit 25. Abnormal thyroid function tests (thyroid-stimulating hormone [TSH], triiodothyronine, free thyroxine [FT4]) out of the normal laboratory value ranges at the time of the Screening Visit. 26. Aspartate aminotransferase, alanine aminotransferase, or gamma-glutamyl transferase > 1.5 times the upper limit of normal at the time of the Screening Visit and at Day -1. 30. Personal history of epilepsy or familial history of epilepsy in a primary relative (eg, sibling, parent, child) as documented by medical records or by the history provided to the Investigator by the subject. Individuals with a personal history of febrile seizures or seizures related to medication, intoxication, or withdrawal.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Incidence of treatment-emergent AEs, serious adverse events, and suspected, unexpected serious adverse reaction | — |
Secondary
| Measure | Time frame |
|---|---|
| - PK (plasma, urine, CSF) - PD - electrocardiograpy effects based on **QTcF | — |
Countries
Netherlands
Outcome results
None listed